Explore the words cloud of the PACE project. It provides you a very rough idea of what is the project "PACE" about.
The following table provides information about the project.
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
|Coordinator Country||Germany [DE]|
|Total cost||7˙595˙715 €|
|EC max contribution||7˙595˙715 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2017-01-01 to 2020-12-31|
Take a look of project's partnership.
|1||CHARITE - UNIVERSITAETSMEDIZIN BERLIN||DE (BERLIN)||coordinator||2˙336˙500.00|
|2||PLURISTEM LTD||IL (HAIFA)||participant||3˙076˙750.00|
|3||PARACELSUS MEDIZINISCHE PRIVATUNIVERSITAT SALZBURG - PRIVATSTIFTUNG||AT (SALZBURG)||participant||687˙250.00|
|4||ICON CLINICAL RESEARCH LIMITED||IE (DUBLIN)||participant||625˙000.00|
|5||ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU||IT (SIENA)||participant||275˙000.00|
|6||TECHNISCHE UNIVERSITAET DRESDEN||DE (DRESDEN)||participant||219˙000.00|
|7||Genome Identification Diagnostics GmbH||DE (Strassberg)||participant||188˙465.00|
|8||ASKLEPIOS KLINIKEN HAMBURG GMBH||DE (HAMBURG)||participant||187˙750.00|
PACE aims to transform the treatment of patients suffering from critical limb ischemia (CLI), a disease with high medical need, because of limited treatment options and poor outcome by applying a novel, off-the-shelf allogeneic placenta-derived stromal cell product (PLX-PAD). Despite improvements in medical care and revascularization, patients with CLI continue to have a high risk of major amputation (below the knee or higher) and cardiovascular death (1-year amputation-free survival <60%; 10-year mortality 70%). CLI has a strong social impact and its incidence is rising worldwide, including in Europe. The prevalence of CLI in the population aged 60–90 years is estimated as 1% (0.5–1.2%) with male to female ratio around 3:1. We will evaluate the efficacy, tolerability and safety of multiple intramuscular injections of HLA-unmatched allogeneic PLX-PAD for the treatment of CLI patients who are unsuitable for revascularization, in a randomized, double-blind, multicentre, placebo-controlled, parallel group phase II study. The European Medicine Agency (EMA) accepted PLX-PAD as pilot project for the new “Adaptive Pathways to Patients” to force timely access for patients to the new therapeutic option. The PACE consortium will go beyond the traditional clinical trial endpoints of safety and efficacy, by state-of-the-art characterizing molecular and functional signature of the PLX-PAD product(s), in depth investigating mechanisms-of-action of PLX-PAD therapy, and exploring biomarkers for understanding response/non-response in particular patients (stratification and therapy response markers). PACE partners are world-leading experts in scalable, clinical grade 3D-cell manufacturing approved by authorities, preclinical and clinical cell therapy, and biomarker analyses with well recognized expertise in designing and performing clinical trials, including those with Advanced Therapy Medicinal Products (ATMPs) integrated with in-patient biomarker and mechanistic side-studies.
|Publications and material for communication (flyers, press release, videos, seminars, publications) third yesr||Websites, patent fillings, videos etc.||2020-04-08 14:23:15|
|Project visual identity||Demonstrators, pilots, prototypes||2020-04-08 14:23:14|
|Project web site||Other||2020-04-08 14:23:14|
|Publications and material for communication (flyers, press release, videos, seminars, publications) 1st year||Websites, patent fillings, videos etc.||2020-04-08 14:23:14|
|Initial dissemination plan||Documents, reports||2020-04-08 14:23:14|
Take a look to the deliverables list in detail: detailed list of PACE deliverables.
|year||authors and title||journal||last update|
Guido Moll, Norman Drzeniek, Julian Kamhiehâ€Milz, Sven Geissler, Petra Reinke
Editorial comment: variables affecting the presence of mesenchymal stromal cells in the peripheral blood and their relationship with apheresis product
published pages: , ISSN: 0007-1048, DOI: 10.1111/bjh.16389
|British Journal of Haematology||2020-04-08|
Behnam Sadeghi, Gianluca Moretti, Fabian Arnberg, Erik SamÃ©n, Bita Kohein, Rusan Catar, Julian Kamhieh-Milz, Sven Geissler, Guido Moll, Staffan Holmin, Olle RingdÃ©n
Preclinical Toxicity Evaluation of Clinical Grade Placenta-Derived Decidua Stromal Cells
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.02685
|Frontiers in Immunology 10||2020-04-08|
Anastazja Andrzejewska, Rusan Catar, Janosch Schoon, Taimoor Hasan Qazi, Frauke Andrea Sass, Dorit Jacobi, Antje Blankenstein, Simon Reinke, David KrÃ¼ger, Mathias Streitz, Stephan Schlickeiser, Sarina Richter, Naima Souidi, Christien Beez, Julian Kamhieh-Milz, Ulrike KrÃ¼ger, Tomasz Zemojtel, Karsten JÃ¼rchott, Dirk Strunk, Petra Reinke, Georg Duda, Guido Moll, Sven Geissler
Multi-Parameter Analysis of Biobanked Human Bone Marrow Stromal Cells Shows Little Influence for Donor Age and Mild Comorbidities on Phenotypic and Functional Properties
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.02474
|Frontiers in Immunology 10||2020-04-08|
Guido Moll *, Martin J. Hoogduijn and James A. Ankrum
Editorial: Safety, Efficacy and Mechanisms of Action of Mesenchymal Stem Cell Therapies
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2020.00243
|Frontiers in Immunology||2020-04-08|
Levent AkyÃ¼z*, Andreas Wilhelm, Florian Butke, Park Su-Jin, Anja Kuckuck, Hans-Dieter
Volk, Gerald GrÃ¼tz
Validation of novel multiplex technologies
published pages: , ISSN: 2424-9106, DOI:
|Advances in precision medicine bi-annual||2020-04-08|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PACE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PACE" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More
Global Alliance for Chronic Diseases SecretariatRead More